Clinical trials · Illinois
Schizophrenia clinical trials in Illinois
We’re tracking 27 recruiting schizophrenia studies with a site in Illinois — including Phase 1, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Illinois
- NCT07459647RecruitingPhase 2
Long-term study of ML-007C-MA for schizophrenia
This trial tests a new drug, ML-007C-MA, for adults with schizophrenia who may benefit from ongoing treatment. It aims to see how safe and effective the drug is over a longer period.
Chicago, IllinoisAges 18–65 - NCT07686263RecruitingPhase 3
Testing a new drug to prevent schizophrenia relapse
This trial tests whether a new oral medication, KarXT, can help prevent a return of schizophrenia symptoms in people who have been stable on treatment. If you've had a hospital stay in the past year and still have some symptoms, you may be able to join.
Chicago, IllinoisAges 18–65 - NCT07615426RecruitingPhase 1
Testing aticaprant with antipsychotic medication for schizophrenia
This study tests whether a new medication called aticaprant is safe and well-tolerated when added to your current antipsychotic medication for schizophrenia. The goal is to see if it could help improve symptoms without causing serious side effects.
Chicago, IllinoisAges 18–55 - NCT05184335RecruitingPhase 3
Brilaroxazine for adults with schizophrenia
This study tests whether brilaroxazine works and is safe for people with schizophrenia. It mainly aims to help people whose symptoms are still present despite prior treatment, while excluding those with certain other diagnoses or substance/drug issues.
Chicago, IllinoisAges 18–65 - NCT07467993RecruitingPhase 2
Testing GXV813 for hospitalized adults with schizophrenia
This trial tests a new drug, GXV813, to see if it helps reduce symptoms in people with schizophrenia who are currently hospitalized due to a sudden worsening of their condition. It compares the drug's safety and effect against a placebo over several weeks.
Chicago, IllinoisAges 18–65 - NCT07410507RecruitingPhase 2
Study of Brenipatide for adults with schizophrenia
This trial tests an investigational drug called brenipatide for people with schizophrenia who are already on a stable medication regimen. The goal is to see if adding this drug helps reduce relapses.
Chicago, IllinoisAges 18–55 - NCT07363577RecruitingPhase 3
Testing LB-102 for adults with acute schizophrenia
This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.
Chicago, IllinoisAges 18–65 - NCT07288567RecruitingPhase 3
KarXT for teens with schizophrenia
This trial tests if a new medicine, KarXT, can safely and effectively treat schizophrenia in adolescents. It may help teenagers who have active symptoms like hallucinations or disorganized thinking.
Chicago, IllinoisAges 13–17 - NCT07191483RecruitingPhase 2
Study of KYN-5356 for cognitive problems in schizophrenia
This trial tests an investigational drug, KYN-5356, to see if it can improve thinking and memory problems in adults with schizophrenia. You may join if your schizophrenia is stable and you take only one antipsychotic medication.
Chicago, IllinoisAges 18–55 - NCT07114874RecruitingPhase 3
A long-term study of a new drug for schizophrenia
This study tests a new medicine called NBI-1117568 for adults with schizophrenia over a longer period of time. Participants will stop their current antipsychotics and take this new drug to see how well it works and how safe it is.
Chicago, IllinoisAges 18–65 - NCT06963034RecruitingPhase 3
Study of a new medicine for adults with schizophrenia
This trial tests an investigational medicine called NBI-1117568 in adults with schizophrenia who are currently having a relapse or worsening of symptoms and need to stay in the hospital. The goal is to see if the medicine is safe and effective.
Chicago, IllinoisAges 18–65 - NCT06961968RecruitingPhase 3
Schizophrenia medication withdrawal study
This study tests whether patients with schizophrenia can safely stop or reduce their current medication without worsening symptoms. It is designed for people who need ongoing psychiatric care.
Chicago, IllinoisAges 18–65 - NCT06740383Recruiting
Study of early psychosis and treatments
This study looks at people who have had psychosis for less than 4 years to understand how their symptoms change over time and how they respond to treatment. By using brain scans and other tests, researchers hope to find better ways to personalize care for early psychosis.
Chicago, IllinoisAges 18–40 - NCT06502964RecruitingPhase 2
ALTO-101 study for schizophrenia cognitive symptoms
This study tests an experimental medication called ALTO-101 for people with schizophrenia who also have cognitive impairment (memory or thinking problems). It aims to see if the drug can improve these symptoms while you continue your current antipsychotic treatment.
Chicago, IllinoisAges 21–55 - NCT06229210RecruitingPhase 3
Lumateperone safety study for children with schizophrenia, bipolar, or autism
This trial tests a medication called lumateperone for children and teens with schizophrenia, bipolar disorder, or autism spectrum disorder. It aims to see if the medicine is safe and tolerable over time.
Naperville, IllinoisAges 5–17 - NCT05303064RecruitingPhase 3
Study of weight gain medicine for teens with certain mood or psychosis
This Phase 3 study tests a treatment aimed at reducing unhealthy weight gain in teens with schizophrenia or bipolar I disorder, using changes in BMI (a height-and-weight measure). It may help families who are concerned about weight changes that can happen with some psychiatric medicines.
Chicago, IllinoisAges 10–17 - NCT07424404RecruitingPhase 3
Long-term safety study of a medication for psychiatric disorders in children and teens
This study tests a combination medicine (xanomeline and trospium chloride) to see if it is safe and tolerable over a longer period for children and adolescents with psychiatric disorders, especially those with autism-related irritability. It may help families understand if this treatment can be used beyond the initial study period.
Chicago, IllinoisAges 5–17 - NCT07853807Recruiting
Thinking and memory study for adults with schizophrenia and healthy volunteers
This study uses computer tasks to learn how people with schizophrenia think, pay attention, and remember. It may help improve future tests and treatments for schizophrenia. Healthy volunteers are also needed to compare results.
Chicago, IllinoisAges 18–59 - NCT07713849Recruiting
Transition care for recent psychosis
This study tests a program to help people recently diagnosed with psychosis (within the last two years) transition from hospital to community care. If you have a psychotic disorder and a caregiver involved in your discharge planning, this could help you.
Chicago, IllinoisAges 18–40 - NCT07379827Recruiting
A study on switching to KarXT for schizophrenia
This trial looks at how well KarXT works and what side effects it might have when people with schizophrenia switch to it from their current antipsychotic medication. It may be an option for those who have started KarXT recently or who plan to switch from their current treatment.
Crystal Lake, IllinoisAges 18 years+ - NCT07369154RecruitingPhase 3
Long-term safety study of an investigational schizophrenia medication
This study is testing how safe and tolerable an investigational medication is over the long term (52 weeks) when added to your current antipsychotic treatment. It's for people with schizophrenia whose symptoms are stable, and it aims to see if the new medication can help without causing serious side effects.
Chicago, IllinoisAges 18–65 - NCT07221877RecruitingPhase 4
Study of KarXT for urological safety in schizophrenia
This study tests a new medicine (KarXT) for schizophrenia, focusing on how it affects urological (bladder and urinary) safety. You'll stop your current antipsychotic and take the study drug to see if it works well and is safe for your urinary system.
Chicago, IllinoisAges 18–65 - NCT07105111RecruitingPhase 4
Valbenazine for tardive dyskinesia after other treatment
This study tests if valbenazine helps adults with tardive dyskinesia whose symptoms continue even after taking or stopping another similar medication. Tardive dyskinesia involves uncontrollable movements from long-term use of certain mental health drugs.
Naperville, IllinoisAges 18 years+ - NCT07101094Recruiting
Study on satisfaction with a new schizophrenia treatment
This study tracks how satisfied people with schizophrenia are with a new combination medicine called xanomeline and trospium chloride (XT). It aims to understand real-world experiences and benefits of this treatment.
Evanston, IllinoisAges 18 years+
Schizophrenia trials by city in Illinois
Where these studies are running in Illinois
Institutions with a site for the recruiting schizophrenia studies listed above.
- Neurocrine Clinical Site · 3 studies
- Uptown Research Institute · 3 studies
- EmVenio Research · 2 studies
- Pillar Clinical Research · 2 studies
- Pillar Clinical Research -Chicago · 2 studies
- Alkermes Investigator Site
- Amr Conventions Research - Illinois
- Baber Research Group
What taking part in a schizophrenia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Schizophrenia trials in other states
Common questions
- Are there schizophrenia clinical trials in Illinois?
- Yes. We're currently tracking 27 recruiting schizophrenia studies with a site in Illinois, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a schizophrenia study in Illinois?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Illinois to take part?
- Not necessarily. These studies have a site in Illinois, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a schizophrenia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New schizophrenia studies open in Illinois regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.